Weitere Suchergebnisse zu "Inogen":The medical technology firm Inogen continues to navigate a challenging period for its stock price, but a significant strategic appointment aims to revitalize its trajectory. Despite this, management has expressed confidence, subsequently raising its full-year revenue guidance to a range of $354 million to $357 million. Strategic Appointment for Digital TransformationAdShould investors sell immediately? Effective September 29, 2025, this appointment strategically positions a leader with a background in digital health platforms. The central question remains whether this new leadership can successfully accelerate Inogen's digital transformation and catalyze a sustained recovery in its equity value.